Actinium Pharmaceuticals to Highlight First-in-Human Phase 1 Study of ATNM-400 a HER3-Targeted Non-PSMA Radiotherapy in Prostate Cancer at ESMO 2026
Actinium Pharmaceuticals (ATNM) announced its first-in-human Phase 1 study of ATNM-400, a HER3-targeted radiotherapy for metastatic castration-resistant prostate cancer, will be presented at ESMO 2026. The study evaluates safety, dosing, and antitumor activity, with potential to address treatment resistance across multiple solid tumors. ATNM-400 targets HER3, distinct from PSMA, and is designed to deliver Actinium-225 to tumor cells.
How this was made
The 30-second read
Why it matters
The announcement introduces a novel therapeutic class, potentially expanding the company's pipeline and market valuation.
Market read
First‑in‑human trial start is a material event for a biotech, likely prompting short‑term buying interest.
What to watch
Funding requirements for later‑stage trials and competition from established PSMA therapies could limit upside.
Background
Actinium Pharmaceuticals (ATNM) focuses on targeted radiotherapies. ATNM‑400 is a HER3‑targeted alpha‑emitter distinct from PSMA approaches.
Ticker impact
Actinium announced the first‑in‑human Phase 1 study of ATNM‑400 for metastatic castration‑resistant prostate cancer, the first public disclosure of this trial.
likely upward pressure as investors price in the new clinical program
First‑in‑human data are material for a biotech; the announcement is the initial disclosure and the market typically reacts favorably to trial initiations.
Market effects
May boost interest in HER3‑targeted radiotherapies and other alpha‑emitter programs in oncology.
Limited to US biotech investors; no broader regional effect.
Modest, as the trial could influence global radiopharma pipelines.
Counterpoint
Trial success is uncertain; early‑stage data could lead to setbacks, so caution against over‑optimism.
Key entities
- companyActinium Pharmaceuticals, Inc.
Developer of ATNM‑400, a HER3‑targeted radiopharmaceutical.
- personJeri Kim, MD
Presenter of the abstract at ESMO 2026.
